Immunoprecise Antibodies Ltd expected to post a loss of 5 cents a share - Earnings Preview

Mindwalk Holdings

25/07/2025 13:53

Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to  show a rise in quarterly revenue when it reports  results on July 29 for the period ending April 30 2025

The Austin Texas-based  company is expected to report a 22.2% increase in revenue to C$7.891 million from C$6.46 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Immunoprecise Antibodies Ltd is for a loss of 5 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $4.00, about 42.3% above its last closing price of $2.31

This summary was machine generated July 25 at 12:53 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)